ID23891A - Senyawa heterosiklik tersubstitusi tergabung - Google Patents

Senyawa heterosiklik tersubstitusi tergabung

Info

Publication number: ID23891A
Authority: ID; Indonesia
Prior art keywords: group; hydrogen atom; heterosiclic; compounds; chem
Prior art date: 1997-10-08

Application number

IDW20000649A

Other languages

English (en)

Indonesian (id)

Inventor

Takashi Fujita

Kunio Wada

Toshihiko Fujiwara

Original Assignee

Sankyo Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-08

Filing date

1998-10-08

Publication date

2000-05-25

1998-10-08 Application filed by Sankyo Co filed Critical Sankyo Co

2000-05-25 Publication of ID23891A publication Critical patent/ID23891A/id

Links

150000001875 compounds Chemical class 0.000 title 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
230000002401 inhibitory effect Effects 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
229910052717 sulfur Inorganic materials 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
-1 2,4-dioxothiazolidin-5-ylmethyl group Chemical group 0.000 abstract 1
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 abstract 1
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 abstract 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Joining Of Building Structures In Genera (AREA)

IDW20000649A 1997-10-08 1998-10-08 Senyawa heterosiklik tersubstitusi tergabung ID23891A (id)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP27606397		1997-10-08

Publications (1)

Publication Number	Publication Date
ID23891A true ID23891A (id)	2000-05-25

Family

ID=17564291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW20000649A ID23891A (id)	1997-10-08	1998-10-08	Senyawa heterosiklik tersubstitusi tergabung

Country Status (24)

Country	Link
US (1)	US6432993B1 (fr)
EP (1)	EP1022272B1 (fr)
KR (1)	KR100666887B1 (fr)
CN (1)	CN1255386C (fr)
AT (1)	ATE267814T1 (fr)
AU (1)	AU740704B2 (fr)
BR (1)	BR9813848B1 (fr)
CA (1)	CA2305807C (fr)
CZ (1)	CZ302475B6 (fr)
DE (1)	DE69824194T2 (fr)
DK (1)	DK1022272T3 (fr)
ES (1)	ES2221203T3 (fr)
HU (1)	HU228193B1 (fr)
ID (1)	ID23891A (fr)
IL (1)	IL135537A (fr)
MX (1)	MXPA00003546A (fr)
NO (1)	NO318070B1 (fr)
NZ (1)	NZ503794A (fr)
PL (1)	PL200859B1 (fr)
PT (1)	PT1022272E (fr)
RU (1)	RU2196141C2 (fr)
TR (1)	TR200000946T2 (fr)
TW (1)	TW475931B (fr)
WO (1)	WO1999018081A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL351878A1 (en) *	1999-04-07	2003-06-30	Sankyo Co	Amino compound derivatives
WO2000061582A1 (fr) *	1999-04-08	2000-10-19	Sankyo Company, Limited	Derives imidazole condenses substitues
AU5570000A (en) *	1999-06-28	2001-01-31	Sankyo Company Limited	Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof
JP2001072671A (ja) *	1999-06-28	2001-03-21	Sankyo Co Ltd	ベンズイミダゾール化合物の合成中間体およびその製造方法
BR0012591A (pt)	1999-07-19	2002-04-09	Sankyo Co	Agente profilático ou terapêutico para câncer
FI20000542A7 (fi) *	2000-03-09	2001-09-10	Nokia Corp	Siirtokapasiteettien sovittaminen pakettivälitteisessä verkossa
WO2002013864A1 (fr) *	2000-08-16	2002-02-21	Sankyo Company, Limited	Preparation medicinale de prevention et traitement du cancer
US6452014B1 (en) *	2000-12-22	2002-09-17	Geron Corporation	Telomerase inhibitors and methods of their use
WO2003033494A1 (fr) *	2001-10-17	2003-04-24	Sankyo Company, Limited	Derive de benzimidazole
WO2003032988A1 (fr) *	2001-10-17	2003-04-24	Sankyo Company, Limited	Composition pharmaceutique
TW200300677A (en) *	2001-12-11	2003-06-16	Sankyo Co	A pharmaceutical composition
WO2004000356A1 (fr) *	2002-06-25	2003-12-31	Sankyo Company, Limited	Composition medicale contenant un diuretique et un activateur du recepteur $g(g) active par la proliferation des peroxisomes (ppar)
WO2004013109A1 (fr) *	2002-08-02	2004-02-12	Sankyo Company, Limited	Derive de resorcinol
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
CN101068770B (zh)	2004-09-28	2012-01-04	三共株式会社	制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006044556A2 (fr) *	2004-10-14	2006-04-27	Galileo Pharmaceuticals, Inc.	Methodes de traitement du diabete
WO2006076598A2 (fr)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Composes heterocycliques bicycliques en tant que modulateurs des recepteurs de canabinoides
US7368458B2 (en)	2005-01-12	2008-05-06	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (fr)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Heterocycles bicycliques servant de modulateurs aux recepteurs cannabinoides
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (fr)	2005-02-10	2009-01-21	Bristol-Myers Squibb Company	Dihydroquinazolinones utilisees comme modulateurs de la 5ht
RU2418788C2 (ru) *	2005-03-10	2011-05-20	Сги Фармасьютиклз, Инк.	Некоторые замещенные амиды, способ их получения и способ их применения
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en)	2005-06-17	2008-01-08	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en)	2005-06-17	2007-07-16	Bristol Myers Squibb Co	Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7795436B2 (en)	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en)	2005-10-26	2013-12-31	Bristol-Myers Squibb Company	Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
EP1982718A4 (fr)	2006-02-09	2010-05-12	Daiichi Sankyo Co Ltd	Composition pharmaceutique anticancereuse
DK2010528T3 (en)	2006-04-19	2018-01-15	Novartis Ag	6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
TW200838512A (en) *	2007-02-08	2008-10-01	Daiichi Sankyo Co Ltd	Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
BRPI0809643A2 (pt)	2007-04-05	2014-11-11	Daiichi Sankyo Co Ltd	Derivados de heteroarila bicíclica fundida
US20090011994A1 (en)	2007-07-06	2009-01-08	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
US8722710B2 (en)	2007-09-26	2014-05-13	Deuterx, Llc	Deuterium-enriched pioglitazone
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
JPWO2010013769A1 (ja) *	2008-07-31	2012-01-12	第一三共株式会社	チアゾリジンジオン化合物の結晶及びその製造方法
WO2010013768A1 (fr)	2008-07-31	2010-02-04	第一三共株式会社	Cristal de composé de thiazolidinedione, et son procédé de production
SG174504A1 (en)	2009-03-27	2011-10-28	Bristol Myers Squibb Co	Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2505587A1 (fr)	2009-11-26	2012-10-03	Daiichi Sankyo Company, Limited	Procédé de fabrication d'un dérivé de 1-méthyl-1h-benzimidazole substitué en 6 et intermédiaire de fabrication issu de ce procédé
US8207351B2 (en) *	2010-04-30	2012-06-26	International Business Machines Corporation	Cyclic carbonyl compounds with pendant carbonate groups, preparations thereof, and polymers therefrom
EP2892896B1 (fr)	2012-09-05	2016-06-29	Bristol-Myers Squibb Company	Antagonistes du récepteur 1 de l'hormone de concentration de pyrrolone ou pyrrolidinone mélanine
EP2892897A1 (fr)	2012-09-05	2015-07-15	Bristol-Myers Squibb Company	Antagonistes du récepteur 1 d'hormone concentrant la mélanine de type pyrrolone ou pyrrolidinone
US20140221369A1 (en) *	2013-02-01	2014-08-07	Deuterx, Llc	5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
JP6800013B2 (ja)	2013-03-14	2020-12-16	ポクセル・ソシエテ・アノニムＰｏｘｅｌＳＡ	重水素化２，４−チアゾリジンジオン及び治療方法
US10188639B2 (en)	2014-01-15	2019-01-29	Deuterx, Llc	Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
WO2020016335A1 (fr)	2018-07-19	2020-01-23	Astrazeneca Ab	Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
US11767317B1 (en)	2020-06-30	2023-09-26	Poxel Sa	Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en)	2020-06-30	2022-05-03	Poxel Sa	Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06779B2 (ja) *	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US5143930A (en)	1990-02-07	1992-09-01	Sankyo Company, Limited	Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
GB9017218D0 (en)	1990-08-06	1990-09-19	Beecham Group Plc	Novel compounds
US5334604A (en)	1990-08-23	1994-08-02	Pfizer Inc.	Hypoglycemic hydroxyurea derivatives
GB9023584D0 (en)	1990-10-30	1990-12-12	Beecham Group Plc	Novel compounds
GB9023585D0 (en)	1990-10-30	1990-12-12	Beecham Group Plc	Novel compounds
CZ289317B6 (cs)	1994-04-11	2002-01-16	Sankyo Company Limited	Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
CZ293016B6 (cs) *	1995-06-01	2004-01-14	Sankyo Company Limited	Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
JP3291164B2 (ja) *	1995-06-02	2002-06-10	日石三菱株式会社	接触分解ガソリンの脱硫方法
US5798375A (en)	1995-07-03	1998-08-25	Sankyo Company, Limited	Treatment of arteriosclerosis and xanthoma
JP3651816B2 (ja) *	1995-07-03	2005-05-25	三共株式会社	動脈硬化症予防および治療剤
IL120443A (en)	1996-03-18	2000-07-16	Sankyo Co	Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
JPH1072371A (ja) *	1996-08-28	1998-03-17	Sankyo Co Ltd	回腸型胆汁酸トランスポーター阻害剤

1998
- 1998-10-08 KR KR1020007003711A patent/KR100666887B1/ko not_active Expired - Fee Related
- 1998-10-08 IL IL135537A patent/IL135537A/en not_active IP Right Cessation
- 1998-10-08 HU HU0003859A patent/HU228193B1/hu unknown
- 1998-10-08 AT AT98947789T patent/ATE267814T1/de active
- 1998-10-08 DK DK98947789T patent/DK1022272T3/da active
- 1998-10-08 DE DE1998624194 patent/DE69824194T2/de not_active Expired - Lifetime
- 1998-10-08 TW TW087116711A patent/TW475931B/zh not_active IP Right Cessation
- 1998-10-08 BR BRPI9813848-0A patent/BR9813848B1/pt not_active IP Right Cessation
- 1998-10-08 EP EP98947789A patent/EP1022272B1/fr not_active Expired - Lifetime
- 1998-10-08 CN CNB988116928A patent/CN1255386C/zh not_active Expired - Fee Related
- 1998-10-08 AU AU94587/98A patent/AU740704B2/en not_active Ceased
- 1998-10-08 PL PL339771A patent/PL200859B1/pl not_active IP Right Cessation
- 1998-10-08 CA CA002305807A patent/CA2305807C/fr not_active Expired - Fee Related
- 1998-10-08 RU RU2000109326/04A patent/RU2196141C2/ru not_active IP Right Cessation
- 1998-10-08 ID IDW20000649A patent/ID23891A/id unknown
- 1998-10-08 PT PT98947789T patent/PT1022272E/pt unknown
- 1998-10-08 TR TR2000/00946T patent/TR200000946T2/xx unknown
- 1998-10-08 WO PCT/JP1998/004548 patent/WO1999018081A1/fr not_active Ceased
- 1998-10-08 MX MXPA00003546A patent/MXPA00003546A/es active IP Right Grant
- 1998-10-08 NZ NZ503794A patent/NZ503794A/xx not_active IP Right Cessation
- 1998-10-08 ES ES98947789T patent/ES2221203T3/es not_active Expired - Lifetime
- 1998-10-08 CZ CZ20001219A patent/CZ302475B6/cs not_active IP Right Cessation
2000
- 2000-04-07 US US09/543,667 patent/US6432993B1/en not_active Expired - Lifetime
- 2000-04-07 NO NO20001816A patent/NO318070B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2305807C (fr)	2008-01-22
CN1255386C (zh)	2006-05-10
ATE267814T1 (de)	2004-06-15
DE69824194D1 (de)	2004-07-01
HUP0003859A2 (hu)	2001-08-28
CN1280570A (zh)	2001-01-17
EP1022272A4 (fr)	2002-07-17
NO20001816D0 (no)	2000-04-07
HK1027354A1 (en)	2001-01-12
TR200000946T2 (tr)	2000-07-21
PL339771A1 (en)	2001-01-02
KR100666887B1 (ko)	2007-01-10
DE69824194T2 (de)	2005-01-13
NO20001816L (no)	2000-06-07
EP1022272B1 (fr)	2004-05-26
RU2196141C2 (ru)	2003-01-10
EP1022272A1 (fr)	2000-07-26
ES2221203T3 (es)	2004-12-16
DK1022272T3 (da)	2004-09-27
PT1022272E (pt)	2004-08-31
PL200859B1 (pl)	2009-02-27
TW475931B (en)	2002-02-11
KR20010030961A (ko)	2001-04-16
IL135537A (en)	2006-08-20
AU740704B2 (en)	2001-11-15
MXPA00003546A (es)	2002-08-06
NZ503794A (en)	2002-09-27
HUP0003859A3 (en)	2005-09-28
US6432993B1 (en)	2002-08-13
AU9458798A (en)	1999-04-27
BR9813848A (pt)	2000-10-03
CA2305807A1 (fr)	1999-04-15
NO318070B1 (no)	2005-01-31
BR9813848B1 (pt)	2011-07-12
CZ302475B6 (cs)	2011-06-08
IL135537A0 (en)	2001-05-20
WO1999018081A1 (fr)	1999-04-15
HU228193B1 (en)	2013-01-28
CZ20001219A3 (cs)	2000-08-16

Publication	Publication Date	Title
DK1022272T3 (da)	2004-09-27	Substituerede, fusionerede, heterocykliske forbindelser
DK1357111T3 (da)	2009-11-02	2-pyridonderivater med affinitet for cannabinoid type 2-receptor
ATE401312T1 (de)	2008-08-15	Pyrimidin-5-carboxamid-derivate
DK1325910T3 (da)	2008-11-10	Aliphatiske nitrogenholdige femleddede ringforbindelser
ATE271045T1 (de)	2004-07-15	Sauerstoffhaltige heterocyclische verbindungen
ATE237612T1 (de)	2003-05-15	Benzofuranderivate
ATE466861T1 (de)	2010-05-15	Aminderivate
DK0695755T3 (da)	1999-06-28	Pyrrolocarbazoler
ATE164844T1 (de)	1998-04-15	Azolverbindungen, ihre herstellung und verwendung als antimykotische mittel
DK0841327T3 (da)	2002-01-21	Triazolantisvampemiddel
ATE504572T1 (de)	2011-04-15	Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
ATE161820T1 (de)	1998-01-15	Carboxylatderivate mit einer die phospholipase a2 hemmenden aktivität
ATE284884T1 (de)	2005-01-15	Triazolderivate mit amidbindungen
ATE119523T1 (de)	1995-03-15	Isochinolinderivate und ihre salze als proteasehemmer.
GB9016799D0 (en)	1990-09-12	Pesticidal heterocyclic compounds
EA200200462A1 (ru)	2002-10-31	Производные 2-арилхинолина, их получение и терапевтическое применение